Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1100
Shown on this page
12
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mount Sinai, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 553–564 of 1,100 matching trials with a site at Mount Sinai, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

NCT06858319
Status at this site: Recruiting
View directory record Official record
Conditions
Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Interventions
zigakibart
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
8
States / cities
Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

NCT06892288
Site status not listed — check the official record
View directory record Official record
Conditions
Phosphomannomutase 2 Deficiency, PMM2-CDG
Interventions
GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label)
Drug
Lead sponsor
Glycomine, Inc.
Industry
Eligibility
4 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

NCT04550481
Site status not listed — check the official record
View directory record Official record
Conditions
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Interventions
Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
111
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Recruiting Phase 4 Interventional

CaOx Stone Prevention

NCT07225764
Status at this site: Recruiting
View directory record Official record
Conditions
Kidney Stones
Interventions
Chlorthalidone, Low oxalate diet
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Recruiting No phase listed Observational

Real World Evidence Clinical Utility Study of KidneyIntelX

NCT04802395
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetic Kidney Disease
Interventions
KidneyIntelX
Diagnostic Test
Lead sponsor
Renalytix AI, Inc.
Industry
Eligibility
23 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Recruiting Not applicable Interventional

The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants

NCT05223192
Status at this site: Recruiting
View directory record Official record
Conditions
Prematurity
Interventions
Music Therapy Entrainment with Ocean Disc Intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
24 Weeks to 37 Weeks
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Recruiting Not applicable Interventional

Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers

NCT07632001
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Interventions
Miro3D Wound Matrix, Standard of Care
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Coconut Creek, Florida • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

NCT06040970
Status at this site: Recruiting
View directory record Official record
Conditions
Ovarian Cancer, Malignant Neoplasm of Uterus
Interventions
Sacituzumab, Cisplatin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Active, not recruiting No phase listed Observational

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

NCT05198284
Site status not listed — check the official record
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Interventions
KidneyIntelX
Diagnostic Test
Lead sponsor
Renalytix AI, Inc.
Industry
Eligibility
23 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Validating CGM for GDM

NCT06858787
Status at this site: Recruiting
View directory record Official record
Conditions
Gestational Diabetes Mellitus (GDM)
Interventions
Continuous glucose monitor
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
New York, New York • Oceanside, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 27, 2026, 4:11 PM EDT
Active, not recruiting Not applicable Interventional

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588
Site status not listed — check the official record
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
24
States / cities
Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 4:11 PM EDT

About this Mount Sinai institution page

What this page lists
ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.